Patents for A61P 35 - Antineoplastic agents (221,099)
01/2009
01/22/2009WO2009010287A2 Specific therapy and medicament using integrin ligands for treating cancer
01/22/2009WO2009010121A1 Phosphorylation of histone h3 at threonine 11 - a novel epigenetic mark for transcriptional regulation
01/22/2009WO2009009952A1 An extract of rehmannia glutinasa libosch. for reducing blood sugar, reducing blood fat, treating leukemia and preparation method and uses thereof
01/22/2009WO2009009919A1 An escherichia coli expressing trail protein and its construction method and applications
01/22/2009WO2009009883A1 An anti-cancer cytotoxic monoclonal antibody
01/22/2009WO2009009882A1 An anti-cancer cytotoxic monoclonal antibody
01/22/2009WO2009009881A1 An anti-cancer cytotoxic monoclonal antibody
01/22/2009WO2009009818A1 Method of treating skin conditions with ovine amniotic fluid using iontophoresis
01/22/2009WO2008142303A3 Use of an anti-cxcr4 antibody for treating cancer
01/22/2009WO2008121876A3 Non-fucosylated antibodies
01/22/2009WO2008121160A3 Optimized antibodies that target cd5
01/22/2009WO2008116161A3 Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
01/22/2009WO2008083367A4 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
01/22/2009WO2008076447A3 Treatments of therapy-resistant diseases comprising drug combinations
01/22/2009WO2008074437A3 Use of gum arabic and/or of an exudate of acacia spec. as angiogenesis inhibitor
01/22/2009WO2008063558A3 Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
01/22/2009WO2008063202A3 Heterobicyclic thiophene compounds for the treatment of cancer
01/22/2009WO2007136465A3 Compositions and methods for fgf receptor kinases inhibitors
01/22/2009US20090023919 Synthesis of temozolomide and analogs
01/22/2009US20090023900 Anti-AlphaVBeta3 Recombinant Human Antibodies, Nucleic Acids Encoding Same
01/22/2009US20090023811 Biphenyl compound selective agonists of gamma RAR receptors
01/22/2009US20090023810 Methods of translation and/or inflammation blockade
01/22/2009US20090023803 Use of cacao polyphenols for treating a prostate hyperplasia, a specific cacao extract and applications
01/22/2009US20090023798 Thiohydroxamates as inhibitors of histone deacetylase
01/22/2009US20090023796 Analogs of Indole-3-Carbinol Metabolites as Chemotherapeutic and Chemopreventive Agents
01/22/2009US20090023795 Kinase Inhibitors And Methods Of Use Thereof
01/22/2009US20090023791 PH-dependent NMDA receptor antagonists
01/22/2009US20090023789 N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants
01/22/2009US20090023786 Histone Deacetylase Inhibitor Prodrugs
01/22/2009US20090023783 (2,4-Dichloro-phenyl)-(3-methyl-6-m-tolyl-benzofuran-2-yl)-methanone; anticarcinogenic, antiproliferative, antitumor agent; solid tumor, metastasis, lymphomas, leukemia; Cell Titre-Glo/High Throughput Assay
01/22/2009US20090023779 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents
01/22/2009US20090023776 Farnesyl protein transferase inhibitor combinations with antiestrogen agents
01/22/2009US20090023775 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt
01/22/2009US20090023770 1-methoxy-2-methyl-3-[(4-nitrophenyl)sulphonyl]indolizine, used as angiogenesis inhibitors
01/22/2009US20090023768 Rapamycin derivatives for treating neuroblastoma
01/22/2009US20090023767 Anticancer agents; initiasting mitosis which causes tumor cell death
01/22/2009US20090023763 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists
01/22/2009US20090023760 anticarcinogenic agent; thymidylate synthase (TS) inhibitors; Tri-tert-butyl N-{N-{4-[N-((6RS)-2-methoxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L- gamma -glutamyl}-D-glutamate
01/22/2009US20090023759 Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase
01/22/2009US20090023753 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents
01/22/2009US20090023747 Cysteine Protease Inhibitors
01/22/2009US20090023745 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors
01/22/2009US20090023743 Inhibitors of protein kinases
01/22/2009US20090023742 Thiazolones for use as pi3 kinase inhibitors
01/22/2009US20090023739 Capase inhibitors and uses thereof
01/22/2009US20090023738 Diaminopyrimidines as modulators of the ep2 receptor
01/22/2009US20090023736 Compounds for treating proliferative disorders
01/22/2009US20090023735 Sulphonamide Derivatives
01/22/2009US20090023734 Treating cell proliferative disorders
01/22/2009US20090023727 Phthalazinone derivatives
01/22/2009US20090023724 Heteroaryl compounds, compositions thereof, and methods of treatment therewith
01/22/2009US20090023722 Amide substituted imidazoquinolines
01/22/2009US20090023719 4-(Benzo[d]dioxol-4-ylamino)- or 4-(indazol-4-ylamino)- substituted 2,4-pyrimidinediamine derivatives: N4-(5-chlorobenzo[d][1,3]dioxol-4-yl)-N2-(2,6-dimorpholinopyridin-4-yl)pyrimidine-2,4-diamine; N-(4,6-dimorpholin-4-ylpyrimidin-2-yl)-N'-(1H-indazol-4-yl)-N'-methyl-pyrimidine-2,4-diamine; anticancer
01/22/2009US20090023718 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives
01/22/2009US20090023710 Compound
01/22/2009US20090023702 Pyridone gpr119 g protein-coupled receptor agonists
01/22/2009US20090023701 Cytokine Inhibitors
01/22/2009US20090023691 Delaying the ageing process and disorders caused by ageing
01/22/2009US20090023680 treating advanced solid cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine
01/22/2009US20090023677 via acyclic nucleoside analogs such as acyclovir and penciclovir; apoptosis
01/22/2009US20090023676 RNA Interference Mediated Inhibition of MAP Kinase Gene Expression or Expression of Genes Involved in MAP Kinase Pathway Using Short Interfering Nucleic Acid (SiNA)
01/22/2009US20090023675 RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
01/22/2009US20090023666 Modulators of Hypoxia Inducible Factor-1 and Related Uses
01/22/2009US20090023659 Using cell surface adhesion proteins specific immunoglobulin to target therapeutics to tumorous; immunodiagnostics; immunotherapy
01/22/2009US20090023656 Combretastatin A4, ombrabulin hydrochloride, or 1-(3-amino-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene with VEGF inhibitor fusion protein VEGF Trap
01/22/2009US20090023650 Treatment of egfr-dependent tumors by abin (a20 -binding inhibitor of nf kappab)
01/22/2009US20090023649 for treating diseases relating to angiogenesis; fusion protein possesses ribosome inactivating activity and ability to bind to cellular vascular endothelial growth factor (VEGF) receptors
01/22/2009US20090023645 AIB1, a novel steroid receptor co-activator
01/22/2009US20090023639 Methods of Treatment
01/22/2009US20090023635 Factor VII or VIIa - Like Molecules
01/22/2009US20090023224 Vascular endothelial growth factor 2
01/22/2009US20090023216 Double-Stranded Oligonucleotides
01/22/2009US20090023207 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
01/22/2009US20090023160 Antibodies specific for CYP1B1
01/22/2009US20090022827 Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells
01/22/2009US20090022816 Storable, consumable pre-nascent iodine
01/22/2009US20090022814 Cancer treatment method
01/22/2009US20090022806 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
01/22/2009US20090022801 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms
01/22/2009US20090022799 Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
01/22/2009US20090022776 Composition and method for treatment and prevention of restenosis
01/22/2009US20090022768 Continuous flow chamber device for separation, concentration, and/or purification of cells
01/22/2009US20090022745 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
01/22/2009US20090022743 Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells
01/22/2009US20090022741 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging
01/22/2009US20090022740 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging
01/22/2009US20090022738 Multispecific deimmunized CD3-binders
01/22/2009US20090022733 Methods for treating Disease with an IL-1R antibody
01/22/2009US20090022727 Injectable, nonaqueous suspension with high concentration of therapeutic agent
01/22/2009US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
01/22/2009US20090022717 Antibodies that bind cxcr7 epitopes
01/22/2009US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
01/22/2009US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
01/22/2009US20090022712 Compositions and Methods for Inhibiting Leukocyte Function
01/22/2009US20090022708 Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
01/22/2009US20090022699 Method Of Genotypically Modifying Cells By Administration Of RNA
01/22/2009US20090022684 Methods for hematopoietic stimulation
01/22/2009US20090022662 Cancerous disease modifying antibodies
01/22/2009US20090022661 Cancerous disease modifying antibodies
01/22/2009US20090022660 Monoclonal antibodies comprising cytotoxic agent capable of inducing antibody dependent cellular cytotoxicity directed towards tumorus tissues